Associated Genetic Biomarkers
Cyclin-dependent kinase 1 (CDK1) is a gene that encodes a member of the serine/threonine protein kinase family. The protein functions as a catalytic subunit of the protein kinase complex referred to as M-phase promoting factor (MPF). The protein plays a regulatory role in the cell cycle.
CDK1 is altered in 0.74% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, oral cavity squamous cell carcinoma, and anaplastic oligodendroglioma having the greatest prevalence of alterations .
The most common alterations in CDK1 are CDK1 Mutation (0.49%), CDK1 Amplification (0.12%), CDK1 Loss (0.04%), CDK1 R275* (0.04%), and CDK1 D262H (0.02%) .
CDK1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains CDK1 status as an inclusion criterion, 1 is phase 2 (1 open).
Trials with CDK1 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is CDK1 Mutation .
Abemaciclib is the most frequent therapy in trials with CDK1 as an inclusion criteria .
Significance of CDK1 in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.